Diabetic Cardiomyopathy: Molecular Pathogenesis, Metabolic Remodeling, and Emerging Pharmacological Targets
Keywords:
Diabetic cardiomyopathy, Mitochondrial dysfunction, AMPK, CardioprotectionAbstract
Background: Diabetic cardiomyopathy (DCM) describes myocardial structural and functional abnormalities associatedwith diabetes that cannot be explained solely by coronary artery disease, hypertension, or valvular disease. Its biology is complex and includes altered insulin signaling, substrate inflexibility, mitochondrial dysfunction, oxidative stress,inflammation, endoplasmic reticulum stress, impaired calcium handling
Downloads
References
Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW, Grishman A. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol. 1972;30(6):595-602.
Jia G, Hill MA, Sowers JR. Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity. Circ Res. 2018;122(4):624-638
Downloads
Published
How to Cite
Issue
Section
License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
NonCommercial — You may not use the material for commercial purposes.
No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.


